- Home
- SLS vs JYNT Comparison
SLS vs JYNT Comparison
Compare SLS & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- JYNT
- Stock Information
- Founded
- SLS 2012
- JYNT 2010
- Country
- SLS United States
- JYNT United States
- Employees
- SLS N/A
- JYNT N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- SLS Health Care
- JYNT Miscellaneous
- Exchange
- SLS Nasdaq
- JYNT Nasdaq
- Market Cap
- SLS 185.3M
- JYNT 170.3M
- IPO Year
- SLS N/A
- JYNT 2014
- Fundamental
- Price
- SLS $1.85
- JYNT $10.06
- Analyst Decision
- SLS Strong Buy
- JYNT Strong Buy
- Analyst Count
- SLS 1
- JYNT 3
- Target Price
- SLS $7.00
- JYNT $16.33
- AVG Volume (30 Days)
- SLS 1.9M
- JYNT 89.7K
- Earning Date
- SLS 11-12-2025
- JYNT 11-06-2025
- Dividend Yield
- SLS N/A
- JYNT N/A
- EPS Growth
- SLS N/A
- JYNT N/A
- EPS
- SLS N/A
- JYNT N/A
- Revenue
- SLS N/A
- JYNT $53,449,713.00
- Revenue This Year
- SLS N/A
- JYNT $8.06
- Revenue Next Year
- SLS N/A
- JYNT $11.18
- P/E Ratio
- SLS N/A
- JYNT N/A
- Revenue Growth
- SLS N/A
- JYNT 277.36
- 52 Week Low
- SLS $0.77
- JYNT $9.58
- 52 Week High
- SLS $2.27
- JYNT $13.47
- Technical
- Relative Strength Index (RSI)
- SLS 52.67
- JYNT 31.98
- Support Level
- SLS $1.69
- JYNT $10.47
- Resistance Level
- SLS $2.01
- JYNT $10.74
- Average True Range (ATR)
- SLS 0.11
- JYNT 0.26
- MACD
- SLS 0.00
- JYNT -0.04
- Stochastic Oscillator
- SLS 50.00
- JYNT 5.26
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.